Chung Kyong-Mee, Suh Yung Jae, Chin Siyung, Seo Daesung, Yu Eun-Seung, Lee Hyun Jeong, Kim Jong-Heun, Kim Sang Wun, Koh Su-Jin
Department of Psychology, Yonsei University, Seoul, South Korea.
Department of Psychiatry and Behavioral Science, National Cancer Center, Goyang, South Korea.
Front Psychol. 2022 Jun 8;13:699168. doi: 10.3389/fpsyg.2022.699168. eCollection 2022.
This pilot study aimed to evaluate the efficacy of a digital cognitive behavioral therapy (dCBT) in patients with cancer experiencing sleep problems.
A total of 57 participants aged 25-65 years (6M/51F with a mean of 42.80 years and a standard deviation of 14.15 years) were randomly assigned to three groups-21 participants to a dCBT program (HARUToday Sleep), 20 participants to an app-based attentional control program (HARUCard Sleep), and 16 participants to a waitlist control group-and evaluated offline before and after the program completion. Of the 57 participants, there were a total of 45 study completers, 15 participants in each group. The dependent variables were sleep quality scores, measured by the Pittsburgh Sleep Quality Index (PSQI) and health-related quality of life scores, measured using the Short-Form 36 (SF-36), and attentional bias scores from a dot-probe computer task.
For both the intention-to-treat ( = 57) and study-completers analyses ( = 45, 15 for each group), a significant increase supported by a large effect size was found in the quality of sleep score of the HARUToday Sleep group compared to both the app-based attentional control and the waitlist control group. However, no significant changes were found in the quality of life and attentional bias scores.
Our results suggest that the HARUToday Sleep app has the potential to serve as an intervention module to enhance the sleep quality of patients with cancer experiencing sleep problems.
本试点研究旨在评估数字认知行为疗法（dCBT）对有睡眠问题的癌症患者的疗效。
共有57名年龄在25至65岁之间的参与者（6名男性/51名女性，平均年龄42.80岁，标准差14.15岁）被随机分为三组——21名参与者接受dCBT项目（HARUToday睡眠），20名参与者接受基于应用程序的注意力控制项目（HARUCard睡眠），16名参与者进入候补对照组——并在项目完成前后进行线下评估。57名参与者中，共有45名研究完成者，每组15名。因变量为睡眠质量得分（采用匹兹堡睡眠质量指数（PSQI）测量）、健康相关生活质量得分（采用简明健康状况调查量表（SF-36）测量）以及点探测计算机任务的注意力偏差得分。
在意向性分析（n = 57）和研究完成者分析（n = 45，每组15名）中，与基于应用程序的注意力控制组和候补对照组相比，HARUToday睡眠组的睡眠质量得分均有显著提高，且效应量较大。然而，生活质量和注意力偏差得分未发现显著变化。
我们的结果表明，HARUToday睡眠应用程序有潜力作为一种干预模块，提高有睡眠问题的癌症患者的睡眠质量。
